With multiple immunotherapy-based treatment options available for the frontline treatment of advanced/metastatic non-small cell lung cancer (NSCLC), clinicians require updates that inform individualized treatment planning. This interactive multicomponent program provides a review of current evidence-based guidelines and clinical data, including recent updates presented at ASCO, regarding optimal use of immune checkpoint inhibition for metastatic NSCLC. The array of resources and tools offered will help you use best practices in your clinical practice that incorporate shared decision-making and the multidisciplinary team.

RELEASED DATE: July 31, 2025
EXPIRATION DATE: July 31, 2026

This program will unpack the latest clinical insights in NSCLC, including newly presented data from ESMO on ICI monotherapy and combination strategies. Through real-world clinical cases, participants will apply emerging efficacy, safety, and biomarker evidence to personalize treatment plans and strengthen proactive approaches for monitoring and managing immune-related adverse events. Faculty will guide learners in translating rapidly evolving science into practical, patient-centered decision-making across the lung cancer care continuum.

RELEASED DATE: November 21, 2025
EXPIRATION DATE: November 21, 2026

This activity aims to enhance clinicians’ expertise in managing lung cancer in veterans by improving their ability to implement effective lung cancer screening strategies, apply precision oncology through biomarker-driven approaches, select appropriate targeted therapies across various stages of NSCLC treatment, and optimize patient outcomes by proactively addressing immune-related adverse effects associated with immune checkpoint inhibitor therapy.

RELEASED DATE: January 06, 2026
EXPIRATION DATE: January 06, 2027